Peptide index (A–Z)

Advanced bone anabolic

FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.

First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead).

FDA-approved bone resorption inhibitor

Synthetic ADH analog (DDAVP) FDA-approved for diabetes insipidus, nocturnal enuresis, and bleeding disorders

Weekly GLP-1 (Trulicity)

FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US.

Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.

The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.

FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome

FDA-approved GLP-1 for weight loss

PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026.

FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988

Oral GLP-1

Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.

PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026.

Sexual function peptide

Investigational triple agonist (GIP/GLP-1/glucagon). TRIUMPH-1 Phase 3 (May 2026): 28.3% body weight loss at 80 weeks. FDA submission anticipated Q3–Q4 2026.

Weight loss, blood sugar control

FDA-approved bone builder

GHRH for visceral fat

Dual GIP/GLP-1 agonist for weight loss